구조모아 (StructureMoa)항암 chemical structure spider web
방문프로그램 상세에서 관심 등록 후 2개 이상 모으면 여기서 한 번에 비교할 수 있습니다.
표가 넓으면 좌우로 스크롤하세요. 핵심 비교 모드에서는 중요 항목만 표시됩니다.
| 항목 | tirzepatide (Mounjaro / Zepbound, Mounjaro, Zepbound, LY3298176) Eli Lilly·GLP-1 / GIP receptor 269 trials·t½ 5 h |
|---|---|
Overview Program | Mounjaro / Zepbound (tirzepatide) |
Overview Company | Eli Lilly |
Overview Modality | ANTIBODY |
Overview Target | GLP-1 / GIP receptor |
Overview Indication | Type 2 diabetes, chronic weight management |
Overview Phase | APPROVED |
Overview Status | APPROVED |
Overview Content status | Curated Core |
Overview Data Confidence | Data Confidence · High |
Overview Development Signal | Development Signal · Established |
Overview Approval status | FDA approved |
Positioning Key differentiator | Dual incretin mechanism vs GLP-1-only agonists |
Positioning Known limitation | GI side effects during titration; individualized dose escalation required. |
MoA Mechanism | Tirzepatide is a 39-amino-acid peptide activating both GIP and GLP-1 receptors, enhancing insulin secretion, reducing glucagon, slowing gastric emptying, and promoting weight loss via combined incretin effects. |
MoA Biomarker | HbA1c, body weight, lipids. |
PK/PD Half-life | 5 h |
PK/PD Species | Mouse, HbA1c ↓2.0%+ |
PK/PD Animal (cat.) | Mouse |
PK/PD Experiment | pharmacokinetic |
Toxicology Species | Mouse, Rat |
Toxicology Major finding | GI events (nausea, diarrhea) most common; gallbladder disease; thyroid C-cell rodent findings. |
Toxicology CRS | N/A |
Clinical Safety signal | GI events (nausea, diarrhea) most common; gallbladder disease; thyroid C-cell rodent findings. |
Clinical Program phase | APPROVED |
Clinical Trial activity | No active/completed counts |
Preclinical Animal (cat.) | Mouse |
프로그램 상세에서 관심 등록 후 2개 이상 모으면 여기서 한 번에 비교할 수 있습니다.
표가 넓으면 좌우로 스크롤하세요. 핵심 비교 모드에서는 중요 항목만 표시됩니다.
| 항목 | tirzepatide (Mounjaro / Zepbound, Mounjaro, Zepbound, LY3298176) Eli Lilly·GLP-1 / GIP receptor 269 trials·t½ 5 h |
|---|---|
Overview Program | Mounjaro / Zepbound (tirzepatide) |
Overview Company | Eli Lilly |
Overview Modality | ANTIBODY |
Overview Target | GLP-1 / GIP receptor |
Overview Indication | Type 2 diabetes, chronic weight management |
Overview Phase | APPROVED |
Overview Status | APPROVED |
Overview Content status | Curated Core |
Overview Data Confidence | Data Confidence · High |
Overview Development Signal | Development Signal · Established |
Overview Approval status | FDA approved |
Positioning Key differentiator | Dual incretin mechanism vs GLP-1-only agonists |
Positioning Known limitation | GI side effects during titration; individualized dose escalation required. |
MoA Mechanism | Tirzepatide is a 39-amino-acid peptide activating both GIP and GLP-1 receptors, enhancing insulin secretion, reducing glucagon, slowing gastric emptying, and promoting weight loss via combined incretin effects. |
MoA Biomarker | HbA1c, body weight, lipids. |
PK/PD Half-life | 5 h |
PK/PD Species | Mouse, HbA1c ↓2.0%+ |
PK/PD Animal (cat.) | Mouse |
PK/PD Experiment | pharmacokinetic |
Toxicology Species | Mouse, Rat |
Toxicology Major finding | GI events (nausea, diarrhea) most common; gallbladder disease; thyroid C-cell rodent findings. |
Toxicology CRS | N/A |
Clinical Safety signal | GI events (nausea, diarrhea) most common; gallbladder disease; thyroid C-cell rodent findings. |
Clinical Program phase | APPROVED |
Clinical Trial activity | No active/completed counts |
Preclinical Animal (cat.) | Mouse |
추천 비교
추천 비교